# Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

> **NCT00021255** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 3222 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel
- **DRUG:** Herceptin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00021255
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 3222 (ACTUAL)
- **Last updated:** 2016-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00021255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00021255, "Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00021255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*